OpenArc Corporate Advisory’s Quest Diagnostics DGX Stock Holding History

OpenArc Corporate Advisory’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$322K	Buy	1,517 +377	+33%	+$74K	﹤0.01%	609
2026 Q1	$223K	Buy	+1,140	New	+$221K	﹤0.01%	649

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

OpenArc Corporate Advisory's DGX Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Quest Diagnostics (DGX) stake by 33% in Q2 2026, buying an estimated $74K and bringing the position to 1,517 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #609.

OpenArc Corporate Advisory first reported a position in DGX in Q1 2026 and has held it in 2 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

OpenArc Corporate Advisory held 1,517 shares of Quest Diagnostics worth $322K as of Q2 2026.
OpenArc Corporate Advisory bought 377 Quest Diagnostics shares in Q2 2026, an estimated $74K.
Quest Diagnostics made up ﹤0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #609 holding.
OpenArc Corporate Advisory first reported a position in Quest Diagnostics in Q1 2026 and has held it in 2 quarters since.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.